All Industries

Santacruz Silver Mining Executive Chairman Arturo Prestamo Provides Production Update

Santacruz Silver Mining

Santacruz Silver Mining Executive Chairman and Interim CEO Arturo Prestamo joined Steve Darling from Proactive to provide a production update on the company's various mining operations. The company processed 470,749 tonnes of material and produced 4,478,122 silver equivalent ounces, including 1,581,949 ounces of silver, 22,847 tonnes of zinc, 2,953 tonnes of lead, and 256 tonnes of copper. Prestamo told Proactive that Santacruz has successfully restructured its debt with Glencore, resulting in enhanced financial flexibility and a more robust balance sheet. This strategic move has bolstered the company’s financial position and should allow for better optimization of Santacruz’s core business activities and the pursuit of long-term growth. During the first quarter, production at its Bolivian mines faced several disruptions due to various events, including national holidays and the national population census. Caballo Blanco experienced a challenging quarter due to additional production disruptions caused by safety training and mining in areas with lower silver grades. However, the preparation of new areas is progressing well, thanks to the integration ramp. Caballo Blanco is expected to mine areas with higher silver grades in the coming months, and together with fewer operational disruptions, the company expects a better performance. Préstamo also highlighted the advantageous metal pricing, especially for silver and zinc, and expressed confidence in the company's ability to generate strong cash flows. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

June 10, 2024 11:05 AM Eastern Daylight Time

Video

News Release

Neometals Ltd: Advancing Lithium Battery Recycling and Hydrometallurgical Projects

Neometals Ltd

Neometals Ltd, headquartered in Western Australia, has recently upgraded its listing on the OTC market in the United States. General Manager for Investor Relations, Jeremy McManus, detailed the company's focus on developing mineral processing technologies aimed at recovering critical materials from high-value waste, transitioning from its roots in exploration and mining to a focus on the circular economy. The company operates three main business units: lithium battery recycling, lithium chemical production, and vanadium chemicals, all based on hydrometallurgical techniques. Their flagship project, a lithium battery recycling initiative, is a 50/50 joint venture with a German plant builder named Primobius. This joint venture includes operations in Germany and a pilot facility for Mercedes-Benz. McManus highlighted a recent opportunity to acquire 80% of a business with its own technology, which has shown promising interim results from test programs. In the next three to six months, Neometals aims to advance the construction and commissioning of their German facility for Mercedes-Benz, pursue industrial partnerships for their vanadium and lithium business units, and make an investment decision on their precious metals project in Colorado by August. The US market is significant for Neometals due to opportunities for selling recycling plants and raising awareness. The company's recent OTC listing upgrade is a strategic move to enhance visibility and engagement in the American market. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

June 10, 2024 10:57 AM Eastern Daylight Time

Video

Lily Introduces YUZU Flavor

Drink Lily

Lily, the emerging New York-based beverage brand, knows non-alcoholic consumers want something more than just a seltzer and lime. This pushed them to create their latest offering, the vibrant and tart new flavor harnessing the adaptogenic power of the Egyptian Water Lily, YUZU. Starting today, Lily YUZU will launch on the brand’s website and will be available to ship directly to Lily fans nationwide. Lily’s Latinx co-founder, Isaac Lliguin, who oversees testing of the brand’s flavors, sought to create something memorable for consumers resulting in this anxiety soothing and mood enhancing beverage. The result is a complex, zesty blend with a tart citrus burst accompanying every sip. “Our first flavor, BLOOD ORANGE, was designed to be sweet and refreshing, while YUZU is for those pallets who prefer a sharp crisp taste that grabs their attention,” says Lliguin. “We had to blend the zestiness of this Japanese citrus with subtle notes of apricot, to get the balance right with the unique flavor of our star ingredient: the Egyptian Water Lily.” There’s more than just flavor to get excited about here. Lily’s YUZU formula contains adaptogens, nootropics, and antioxidants designed to support a healthy lifestyle, keeping Lily’s brand mission to support comprehensive wellness in mind. With only 35 calories, 7 grams of sugar, and no artificial ingredients, each can is something you can feel good about. Bursting with refreshing zest and brightness, this invigorating blend features Yuzu, mood-boosting Egyptian Water Lily, soothing Ashwagandha, and energizing Green Tea. After their inaugural flavor, BLOOD ORANGE, sold out just 5 months after launch, Lily is excited to announce an exclusive deal with New York City based NA distributor, Tristate Zero Proof. All Lily’s are sold in a 12 fl. oz. aluminum can with a suggested retail price of $5.00/unit in stores and $108 for a 24-unit case via e-commerce. “I’ve always loved drinks that give your taste buds a complex sensory experience. With each sip of YUZU you’ll be greeted by that invigorating citrus zing” says Lliguin. “We were shocked by how quickly our first flavor sold out, and even more so, by the demand for more flavors and we are excited to bring this addition to offer more versatility to our customers.” Lily is a sparkling non-alcoholic functional beverage infused with powerful adaptogens and nootropics, designed to give you a guilt-free energy boost and a clean buzz. Lily was created for all of life's situations—whether it's soothing anxiety before a big meeting, boosting energy before a workout class, or providing a light buzz during a night out with friends. Its unique extraction process places Lily as the sole beverage in the market utilizing the calming and mood-enhancing properties of the Egyptian Water Lily. Lily is sold online at www.drinklily.com and in select retailers in the New York metropolitan area. Contact Details Lily Gabrielle Perez press@drinklily.com Company Website https://www.drinklily.com/

June 10, 2024 10:00 AM Eastern Daylight Time

Image

CSJ Consulting Limited Announces Strategic Collaborations with BNP Paribas and Société Générale

BNP Paribas SA

CSJ Consulting Limited, a leader in the fixed rate bond market with over two decades of proven expertise, is thrilled to confirm its new strategic collaborations with two of Europe’s most prestigious financial institutions: BNP Paribas and Société Générale. These partnerships mark a significant milestone in CSJ Consulting Limited’s ongoing commitment to enhancing its service offerings and expanding its global footprint. These strategic alliances underscore CSJ Consulting Limited’s dedication to leveraging collective strengths to foster innovation, enhance client services, and deliver superior financial products tailored to the evolving needs of the market. “These partnerships are a testament to our sustained efforts to enhance our strategic positioning and expand our operational capabilities across key global markets,” said Charles Brooks Senior Advisor at CSJ Consulting Limited. “By aligning with these distinguished institutions, we are poised to drive innovation and provide our clients with a more diverse range of fixed rate market opportunities.” The collaboration with BNP Paribas and Société Générale will allow CSJ Consulting Limited to deepen its market penetration and strengthen its presence across pivotal financial hubs in Europe. This expansion is geared towards harnessing local expertise and insights, which are critical in navigating the complexities of regional markets. These partnerships will also enable CSJ Consulting Limited to enhance its analytical capabilities and broaden its perspective on global economic trends. “Entering these collaborations allows us to share knowledge, risk management strategies, and resources, positioning us to better meet the financial goals of our clients,” added Richard Martin Hill. “We are especially excited about the potential these partnerships have to enhance our analytical capabilities and broaden our perspective on global economic trends.” As part of its strategy, CSJ Consulting Limited has meticulously planned these collaborations to align with its core values and long-term objectives. The company remains focused on its mission to deliver high-quality, customized bond brokerage services by continuously adapting to the needs of the market and enhancing its operational efficiency. The formal announcements of each partnership will include details of the collaborative efforts and expected impacts on the market, alongside insights into how these will benefit existing and future clients of CSJ Consulting Limited. The company anticipates that these strategic collaborations will not only bolster its market position but also enhance its ability to innovate within the fixed rate bond sector. For ongoing updates and more information about CSJ Consulting Limited and its services, please visit www.csj-consulting.com About CSJ Consulting Limited CSJ Consulting Limited is a premier bond brokerage firm renowned for its expertise in the fixed rate bond market. With over 20 years of industry experience, CSJ Consulting Limited is committed to delivering tailored financial solutions that meet the unique needs of each client, backed by a deep understanding of market dynamics and exceptional client service. News Source: Pinion Newswire Disclaimer: The information mentioned in the press release is provided by source CJS Consulting. PinionNewswire and its distribution partners are not directly or indirectly responsible for any claims made in the above statements. Contact the vendor of the product directly for any queries/issues. Contact Details CSJ Consulting Charles Moss charles.moss@csj-consulting.com Company Website https://csj-consulting.com/

June 10, 2024 09:22 AM Eastern Daylight Time

ACTIVATE’S CUTTING-EDGE GAMING EXPANDS TO MISSISSAUGA

Activate

Activate, the world’s first active gaming facility and TikTok viral sensation, is thrilled to announce its fourth location in Ontario, set to open in Mississauga on June 14, 2024. Following successful openings in Brampton, Burlington, and Scarborough, Activate offers an entertainment option like no other of unparalleled excitement that has sparked a nationwide gaming sensation. Activate Mississauga is located at 5980 Mclaughlin Rd, Unit 1, Mississauga, ON, L5R 3X9. Founded in Canada, Activate is transforming the gaming landscape, counting 13 locations across Canada and 10 locations in the United States with no signs of slowing down. Attracting over 2.6 million players worldwide, the experience blends cutting-edge technology with action-packed challenges for an adrenaline-fueled adventure. "Activate's expansion into Mississauga marks an exhilarating milestone in our journey to revolutionize gaming entertainment," expressed Adam Schmidt, Founder & CEO of Activate. "We are thrilled to introduce our action-packed challenges to a new market in Ontario. Our mission is to deliver an unforgettable social adventure, uniting friends and families and creating lasting excitement, camaraderie, and cherished memories." With over 9,000 square feet of fun, Activate Mississauga’s new state-of-the-art gaming facility welcomes all ages and skill levels, encouraging players to explore and create their own unique experiences. Here’s what to expect: Guests can sign up in groups of two to five players Through progress tracking via Activate’s high-tech electronic RFID wristbands, players can rack up points, leveling up and earning prizes along the way. Top gaming rooms include the TikTok viral sensation Mega Grid with 500+ multi-activated rainbow-coloured tiles, blasting the beaming bullseye in a game called Strike, and feel like a modern day spy in the Laser room. Try Level 1 easy or take it to Level 10 extreme. Play as a team in cooperative mode, or challenge your friends in competitive mode games. In addition to Mississauga, Activate can be found in major Canadian markets such as Calgary, Edmonton, Winnipeg, Halifax, and Brampton, along with U.S. markets such as Houston, Dallas, Chicago, Atlanta, and New Jersey. Additional Activate locations are set to open in 2024 across Canada in markets such as Southern Ontario, Saskatchewan and B.C, along with internationally, including Dubai opening in the Fall, 2024 and launching in the UK in 2025. Today, Activate operates over 30 locations across Canada and the U.S. PLAN YOUR VISIT Book in advance to save time and ensure your preferred time is available. Each game lasts 1-3 minutes. The full gaming experience lasts 75 minutes. Complete the waiver required for you to play in advance. Wear activewear and indoor runners. Age requirements: 10 and older. Where: 5980 Mclaughlin Rd, Unit 1 Mississauga, ON, L5R 3X9. When: Sun-Thurs 9:30 am - 10:00 pm, Fri-Sat 9:30 am - 11:00 pm. For a sneak peek into Activate’s dynamic gaming experience, and to keep tabs on the Activate Mississauga grand opening, click here. Join the Inner Circle to be the first to hear about new locations, behind-the-scenes information, deals, and more. Please find imagery assets here. Activate is the world’s first active gaming experience where players #EnterTheGame. Activate offers a unique blend of physical activity and gaming that promotes a healthy lifestyle. Each Activate location provides fun and interactive rooms for players to compete, earn stars and track achievements. With the global headquarters located in Winnipeg, Canada, Activate has grown to 30 locations across Canada, the U.S. and now the world! To join the active gaming movement, visit playactivate.com. Follow Activate on social media: Facebook: Activate Instagram: @activategames TikTok: @activategames Contact Details Jive PR + Digital Jalila Singerff +1 613-614-6777 jalila@jiveprdigital.com Company Website https://playactivate.com

June 10, 2024 09:07 AM Eastern Daylight Time

AmeriLife and Succession Capital Alliance Partner to Expand Distribution Platform for Advanced Life Insurance Solutions

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that it has partnered with Succession Capital Alliance (“SCA”), the innovator behind premium financing for life insurance and a leading provider of advanced life insurance solutions for financial professionals and their high-net-worth and ultra-high-net-worth clients. Per the agreement, terms of the deal were not disclosed. “Succession Capital Alliance stands out in our industry for its unique approach to serving the high-net-worth life insurance market,” said Scott R. Perry, chairman and CEO of AmeriLife. “I’m excited to welcome Julian Movsesian and his team to AmeriLife as our newest partners. Succession represents a powerful addition to our growing distribution, and I look forward to working together.” Founded in 2004, SCA is known industrywide for its proprietary, nationally recognized Capital Maximization Strategy℠, an innovative strategy that finances policy premiums through custom loans tailored to each client’s unique circumstances to maximize the value of their life insurance assets. This approach – coupled with deep relationships with top carriers and financial institutions – has set SCA apart in the high-net-worth space and has helped financial professionals place more than $60 billion of life insurance and $6 billion of financed life premium since inception. Now, alongside AmeriLife, SCA will gain access to best-in-class shared services and one of the largest wealth distribution networks in the industry to expand its market opportunities and accelerate its already impressive growth. “Over the past 20 years, Succession Capital Alliance has grown into the premier partner for elite advisors across the nation in the advanced life insurance space,” said president and CEO Julian Movsesian. “Our partnership with AmeriLife will enable us to get to the next level, as it offers SCA the ability to expand our distribution channels and leverage AmeriLife’s technology, shared services, and deep analytical capabilities. I couldn’t be more excited for our team and the financial professionals we serve.” As AmeriLife Wealth Group continues to break through traditional distribution models, the addition of Succession Capital Alliance will help drive and fortify its wealth protection business, arming AmeriLife’s growing wealth affiliate network with advanced life, tax, estate, and succession planning solutions in service to the company’s holistic approach to the markets it serves. “Today’s announcement is another critical milestone achieved for AmeriLife Wealth Group and our ability to grow and sustain the next generation of wealth firms and their financial professionals,” said Mike Vietri, Chief Distribution Officer for AmeriLife Wealth Group. “SCA provides a distinctive offering that will not only elevate our life insurance business, but also expand protection solutions for more agents and their clients.” ### About Succession Capital Alliance Succession Capital Alliance, headquartered in Newport Beach, California, is the gold standard in advanced life insurance planning for advisors and their high-net-worth clients. With a singular focus on maximizing the performance of life insurance assets through Premium Financing, SCA leverages the Capital Maximization Strategy to provide leverage within a client's portfolio. For additional information, please visit SuccessionCapital.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and financial professionals and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 media@amerilife.com Succession Capital Alliance Adrina Movsesian amovsesian@successioncapital.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

June 10, 2024 09:00 AM Eastern Daylight Time

BGX-Black Gold Exploration CEO Francisco Gulisano on company projects and prospects

BGX Black Gold Exploration

BGX Black Gold Exploration Ord Shs (CSE:BGX) CEO Francisco Gulisano provides an overview of the company in an interview with Proactive's Stephen Gunnion. Black Gold Exploration is involved in the exploration of natural resources, primarily in Argentina and other American countries. Currently, it is focused on the El Carmen hydrocarbon project along the northern margin of the San Jorge Cretaceous age sedimentary basin, where it aims to certify resources. Gulisano highlighted the company's plans for seismic and drilling operations, mentioning its efforts to manage environmental impact. Additionally, the company is pursuing new projects in Argentina, where the government is supportive of foreign investment and offers tax benefits for exploration activities. The new president's pro-investment stance is seen as a positive development for the company. Gulisano mentioned the environmental and engineering agreements in place with the government to facilitate their operations. Regarding the El Carmen basin, Gulisano noted the presence of natural gas and the potential for oil resources, emphasizing ongoing exploration efforts. He mentioned the commencement of environmental jobs and surveys in the area and promised updates on their progress. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

June 10, 2024 09:00 AM Eastern Daylight Time

Video

AI's Promise On Display: BEN Collaborates With SAIL, Of Weill Cornell Medical Center, To Explore AI For Training Doctors, Improving Patient Outcomes

Benzinga

By Meg Flippin, Benzinga AI is taking off and that’s not lost on Brand Engagement Network Inc. (NASDAQ: BNAI) investors. The maker of AI assistants and avatars just closed a private placement, raising $4.95 million from a group of existing investors. That gives BEN the firepower to continue to develop its AI assistants in-house and through buys. With its human-like AI assistants, BEN is improving businesses’ customer service, productivity and performance, going after markets with a massive workforce gap and an opportunity to transform how consumers engage with networks, providers and brands. The company’s secret sauce is a broad portfolio of conversational AI applications that drive better customer experience, increased automation and operational efficiencies. Take its virtual adherence assistant for the healthcare industry as one example. BEN says its conversational AI can improve patient experiences and medication understanding, leading to better outcomes. Or its “Remember Me” technology which syncs digital and physical interactions for an integrated, personalized customer experience. Investor Show Of Confidence Those advances and many others the company has made since launching its U.S. business in 2018 underpin the why of the recent deal with its existing investors. “The private placement represents a powerful vote of confidence in our strategy from our board, executive team and our existing investors,” said Chairman Chris Gaertner. “This investment will allow BEN to continue to fund its business plan as it seeks to execute on its growth and revenue strategies.” The investment comes as the AI market is taking off, as new use cases validate this transformational technology. The AI market is forecast to soar to $1.3 trillion in the years to come, growing at a CAGR of 42% over the next decade. Rising demand for generative AI products could add about $280 billion of new software revenue, driven by specialized assistants, new infrastructure products and copilots that accelerate coding. Not only did the investors double down on BEN, but they were willing to do so at a premium, purchasing warrants and stock at $2.50 a share – materially above where shares were trading at the time. Some of the investors agreed to provide BEN with additional capital through the exercise of their warrants if the company is unable to raise an additional $3.25 million by October 31, bringing the total investment to $8.25 million. That gives BEN a lot of capital to use to strike up partnerships and make buys. Deep Management Bench It's an area that Michael Zacharski, now co-CEO of BEN after the promotion of Paul Chang to the newly created role of co-CEO, will head up. Zacharski has more than 15 years of experience in the tech industry, making a name for himself for his ability to drive growth, optimize operations and spearhead M&A. “This is a pivotal time for the AI industry, and we’re excited about the prospect of partnering with organizations that complement our vision and capabilities,” said Zacharski. “I am excited to focus on furthering the company’s M&A strategy, which we believe will be core to our business strategy moving forward.” Chang, who has been global president since May 2023, will oversee commercial operations as co-CEO, focusing on validating the market and growing the business commercially. Chang spent 18 years at IBM (NYSE: IBM) creating new markets for emerging technologies as well as several start-ups. “I am thrilled to take on the role of co-CEO,” said Chang. “As we transition into delivering value to our customers by commercializing our safe and comprehensive Gen AI Platform, BEN is well positioned both financially and technologically to execute our plans. With our unique design and architecture as well as portfolio of patents, we hope to demonstrate to the market that our AI Assistants are ready to contribute to businesses in areas that can increase CX, help to complete tasks and fuel their growth.” Rounding out the C-Suite at BEN is Chief Financial Officer Bill Willams. Williams brings over twenty years of experience in corporate finance, legal, technology and management consulting to BEN. He is an expert in driving growth, innovation and value creation for emerging growth companies. AI is taking off, and BEN wants to be a leader in helping businesses streamline operations and enhance customer service with this transformational technology. With fresh cash in its coffers and the backing of a supportive board and investors, BEN seems like an AI story to follow. Featured photo by Steve Johnson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 10, 2024 08:45 AM Eastern Daylight Time

Image

Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors

Benzinga

By Kyle Anthony, Benzinga Elicio Therapeutics (NASDAQ: ELTX) has announced that preliminary data from their AMPLIFY-7P Phase 1a Study of ELI-002 7P in patients with mKRAS-driven solid tumors was well tolerated with T cell responses correlating with a reduction in tumor biomarkers at the recommended Phase 2 dose (“RP2D”). Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative lymph node-targeted immunotherapies to treat aggressive cancers. Given the firm’s expertise in materials science, immunology and oncology, it plans to forge a new path forward for cancer treatment by utilizing its diverse capabilities to fulfill its mission of amplifying the potential of immunotherapies, empowering patients to fight cancer with full force. The initial findings from its study are encouraging, given that KRAS mutated cancers are difficult to target in part due to the number of diverse mutations and bypass resistance mechanisms. “We are encouraged by the first data from the ongoing AMPLIFY-7P trial, which demonstrate ELI-002 7P has a favorable safety profile and early antitumor effects that correlate with induction of T cells specific for multiple KRAS mutations potentially providing broader coverage for patients, said Craig E. Devoe, M.D., MHCM., chief of the Division of Medical Oncology & Hematology and the R.J. Zuckerberg Cancer Center, and scientific investigator at Northwell Health. Elicio Therapeutics Pipeline Elicio Therapeutics’ lead product candidate, ELI-002, is a structurally novel investigational Amphiphile (AMP) cancer vaccine that targets cancers that are driven by mutations in the mKRAS-gene — a prevalent driver of many human cancers. ELI-002 is comprised of two powerful components that are built with Elicio Therapeutics’ AMP technology, consisting of AMP-modified mutant KRAS peptide antigens and an AMP-modified CpG adjuvant that is available as an off-the-shelf subcutaneous administration. ELI-002 2P (2 peptide formulation) is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors following surgery and chemotherapy. ELI-002 7P (7 peptide formulation) is being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer. The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations(G12D, G12R, G12V, G12A, G12C, G12S and G13D) present in 25% of all solid tumors, thereby increasing the potential patient population for ELI-002. Compelling Results From The Ongoing AMPLIFY-7P Phase 1a Study The company reports that the efficacy of ELI-002 7P as a treatment solution was successful in several instances, demonstrating the versatility of the drug and its ability to provide a strong T cell response. The preliminary data findings from the ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P include: ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels ELI-002 7P generated an mKRAS-specific T cell response in 100% of patients including responses targeting all mKRAS mutations enrolled (G12D, V, R and G13D) mKRAS-specific T cells were polyfunctional with 66.7% (4/6) of evaluable patients having both CD8+ and CD4+ responses at the 4.9 mg Phase 2 dose level Tumor biomarker reductions were observed in 5/7 (71%) of evaluable patients at the 4.9 mg Phase 2 dose level ELI-002 7P was shown to induce antigen-spreading with increased T cell responses targeting non-immunizing, personalized tumor neoantigens in 6/6 (100%) of evaluable patients at the 4.9 mg Phase 2 dose level In speaking about these findings, Christopher Haqq, MD, PhD, executive vice president, head of Research and Development and chief medical officer at Elicio Therapeutics, stated, “These early immunogenicity and biomarker response data from ELI-002 7P continue to provide encouraging results showing that our lymph node-targeted approach generates a robust and differentiated T cell response that strongly correlates with tumor biomarker reductions.” “Across two trials, ELI-002 has demonstrated an ability to generate a robust T cell response against all mKRAS mutations of enrolled patients as well as T cell responses against non-immunizing personalized tumor neoantigens. ELI-002’s broader KRAS mutation coverage and higher T cell responses with the 7-peptide vaccine at the Phase 2 dose holds promise for the high unmet need of patients with KRAS-mutated tumors,” Haqq said. The AMPLIFY-7P Phase 1a Study data findings of ELI-002 7P were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 31 to June 4, 2024, in Chicago, IL. The ASCO Annual Meeting is considered the premier international forum for presenting scientific research and state-of-the-art education in clinical oncology. The five-day event attracts 30,000 attendees from around the world. An Immunotherapeutics Company Founded as a spin-out from the Massachusetts Institute of Technology (MIT), Elicio Therapeutics leverages the research of Professor Darrell Irvine, a Howard Hughes Investigator and expert in biomedical engineering and immunology. The company's main innovation, the Amphiphile (AMP) platform, delivers immunotherapeutics directly to the body’s lymph nodes to enhance the immune system's cancer-fighting mechanisms. By delivering cancer immunotherapies to the center of the immune response, Elicio Therapeutics intends to optimize the natural ability of the lymph nodes to educate, activate, and amplify cancer-specific T cells. Elicio Therapeutics' mission is to give patients battling cancer the best possible outcome. The firm’s leadership and scientific advisory board are composed of determined and experienced individuals who are committed to engineering lymph node–targeted immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. The Path Forward Elicio Therapeutics’ recent findings are encouraging news and a tailwind for the firm’s innovation activities. Given the applicability of ELI-002 7P in treating patients with differing cancers, this is a milestone moment for Elicio Therapeutics and an encouraging step forward in the firm’s research and development and eventual commercialization of its treatment offering. As such, the benefit that Elicio Therapeutics provides and the value proposition the firm espouses could continue to grow and have increased industry resonance. Featured photo by CDC on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

June 10, 2024 08:30 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 3604